JO3437B1 - أجسام مضادة محسنة مضادة للفراكتالكين البشري واستخداماتها - Google Patents

أجسام مضادة محسنة مضادة للفراكتالكين البشري واستخداماتها

Info

Publication number
JO3437B1
JO3437B1 JOP/2010/0374A JOP20100374A JO3437B1 JO 3437 B1 JO3437 B1 JO 3437B1 JO P20100374 A JOP20100374 A JO P20100374A JO 3437 B1 JO3437 B1 JO 3437B1
Authority
JO
Jordan
Prior art keywords
antibodies
human
fractalkin
enhanced anti
enhanced
Prior art date
Application number
JOP/2010/0374A
Other languages
Arabic (ar)
English (en)
Inventor
Nishimura Miyuki
Kawano Tetsu
Imai Toshio
Sakamoto Yoshimasa
Original Assignee
Esai R & D Man Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=43922220&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=JO3437(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Esai R & D Man Co Ltd filed Critical Esai R & D Man Co Ltd
Application granted granted Critical
Publication of JO3437B1 publication Critical patent/JO3437B1/ar

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Pain & Pain Management (AREA)
  • Biomedical Technology (AREA)
  • Rheumatology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Transplantation (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
JOP/2010/0374A 2009-10-30 2010-10-27 أجسام مضادة محسنة مضادة للفراكتالكين البشري واستخداماتها JO3437B1 (ar)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US25652109P 2009-10-30 2009-10-30

Publications (1)

Publication Number Publication Date
JO3437B1 true JO3437B1 (ar) 2019-10-20

Family

ID=43922220

Family Applications (1)

Application Number Title Priority Date Filing Date
JOP/2010/0374A JO3437B1 (ar) 2009-10-30 2010-10-27 أجسام مضادة محسنة مضادة للفراكتالكين البشري واستخداماتها

Country Status (33)

Country Link
US (1) US8932592B2 (enExample)
EP (1) EP2493930B1 (enExample)
JP (2) JP5631991B2 (enExample)
KR (2) KR102099596B1 (enExample)
CN (1) CN102597003B (enExample)
AR (2) AR078796A1 (enExample)
AU (1) AU2010312408B2 (enExample)
BR (1) BR112012010266A2 (enExample)
CA (1) CA2778895C (enExample)
CL (2) CL2012001143A1 (enExample)
CY (1) CY1121167T1 (enExample)
DK (1) DK2493930T3 (enExample)
ES (1) ES2698389T3 (enExample)
HR (1) HRP20181973T1 (enExample)
HU (1) HUE041952T2 (enExample)
IL (1) IL219470A (enExample)
JO (1) JO3437B1 (enExample)
LT (1) LT2493930T (enExample)
MX (1) MX2012005052A (enExample)
MY (1) MY158481A (enExample)
NZ (1) NZ599779A (enExample)
PE (1) PE20121645A1 (enExample)
PH (1) PH12012500828A1 (enExample)
PL (1) PL2493930T3 (enExample)
PT (1) PT2493930T (enExample)
RS (1) RS58142B1 (enExample)
RU (1) RU2569109C2 (enExample)
SI (1) SI2493930T1 (enExample)
SM (1) SMT201800637T1 (enExample)
TW (1) TWI414308B (enExample)
UA (1) UA105073C2 (enExample)
WO (1) WO2011052799A1 (enExample)
ZA (1) ZA201203002B (enExample)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9415118B2 (en) * 2013-03-13 2016-08-16 Novartis Ag Antibody drug conjugates
LT3221346T (lt) 2014-11-21 2020-11-10 Bristol-Myers Squibb Company Antikūnai, apimantys modifikuotas sunkiosios grandinės pastoviąsias sritis
KR20230125855A (ko) 2014-11-21 2023-08-29 브리스톨-마이어스 스큅 컴퍼니 Cd73에 대항한 항체 및 그의 용도
EP3159007A1 (en) 2015-10-19 2017-04-26 Eisai R&D Management Co., Ltd. Pharmaceutical composition for treating rheumatoid arthritis
JP2017154975A (ja) * 2016-02-29 2017-09-07 エーザイ・アール・アンド・ディー・マネジメント株式会社 クローン病を治療するための医薬組成物
JP2018070473A (ja) * 2016-10-26 2018-05-10 エーザイ・アール・アンド・ディー・マネジメント株式会社 関節リウマチを治療するための医薬組成物
JP2018177701A (ja) * 2017-04-14 2018-11-15 エーザイ・アール・アンド・ディー・マネジメント株式会社 クローン病を治療するための医薬組成物
WO2020214166A1 (en) * 2019-04-17 2020-10-22 The Governors Of The University Of Alberta Treatment of autoimmune liver disease
EP3960198A4 (en) 2019-04-23 2023-01-11 Eisai R&D Management Co., Ltd. BIOMARKERS FOR TREATMENT OF RHEUMATOID ARTHRITIS
US20230043034A1 (en) * 2019-12-09 2023-02-09 Alexion Pharmaceuticals, Inc. Anti-c5 antibody for the treatment of neuromyelitis optica spectrum disorder
CN113087795B (zh) * 2019-12-23 2025-06-10 上海普铭生物科技有限公司 针对趋化因子cx3cl1的抗体及其应用
CN116472061A (zh) 2020-10-30 2023-07-21 卫材R&D管理有限公司 药物组合物

Family Cites Families (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1990005144A1 (en) 1988-11-11 1990-05-17 Medical Research Council Single domain ligands, receptors comprising said ligands, methods for their production, and use of said ligands and receptors
US6291158B1 (en) 1989-05-16 2001-09-18 Scripps Research Institute Method for tapping the immunological repertoire
US6172197B1 (en) 1991-07-10 2001-01-09 Medical Research Council Methods for producing members of specific binding pairs
US5397703A (en) 1992-07-09 1995-03-14 Cetus Oncology Corporation Method for generation of antibodies to cell surface molecules
WO1994029351A2 (en) * 1993-06-16 1994-12-22 Celltech Limited Antibodies
US6180377B1 (en) 1993-06-16 2001-01-30 Celltech Therapeutics Limited Humanized antibodies
CN1196733A (zh) 1995-06-30 1998-10-21 持田制药株式会社 抗Fas配体抗体和利用抗Fas配体抗体的测定方法
US6114507A (en) 1995-06-30 2000-09-05 Mochida Pharmaceutical Co., Ltd. Anti-Fas ligand antibody and assay method using the anti-Fas ligand antibody
US6096312A (en) 1995-06-30 2000-08-01 Mochida Pharmaceutical Co., Ltd. Agent for suppressing a reduction of CD4+ lymphocytes
WO1997027299A1 (en) 1996-01-24 1997-07-31 Schering Corporation Mammalian cx3c chemokine genes
US6548654B1 (en) 1996-01-24 2003-04-15 Schering Corporation DNA encoding mammalian CX3C chemokine genes
US7115379B1 (en) 1996-01-24 2006-10-03 Schering Corporation Anti-mammalian CX3C cytokine antibodies
US6566503B2 (en) 1996-01-24 2003-05-20 Schering Corporation Mammalian CX3C chemokine
AU730989B2 (en) 1996-05-07 2001-03-22 Millennium Pharmaceuticals, Inc. Neurotactin and uses therefor
US6043086A (en) * 1996-05-07 2000-03-28 Millenium Biotherapeutics, Inc. Neurotactin and uses therefor
SE9802729D0 (sv) 1998-08-13 1998-08-13 Astra Pharma Prod Novel Compounds
US6420121B1 (en) 1998-08-31 2002-07-16 Oregon Health Sciences University Prevention of cell migration initiation with CMV US28 receptor antagonists
JP2001218581A (ja) 1999-11-30 2001-08-14 Eisai Co Ltd モノクローナル抗体の作製法
US6677321B1 (en) 1999-12-09 2004-01-13 Bruce Levin Methods and compositions for treatment of inflammatory disease
AU2000273378A1 (en) 2000-02-18 2001-08-27 Millennium Pharmaceuticals, Inc. Therapeutic methods that target fractalkine or cx3cr1
US8647612B2 (en) 2008-03-05 2014-02-11 Encore Health, Llc Dithiol compounds, derivatives, and treatment of presbyopia
US20020192212A1 (en) * 2001-03-19 2002-12-19 Toshio Imai Uses of anti-CX3CR1 antibody, anti-fractalkine antibody and fractalkine
JP4263391B2 (ja) * 2001-03-19 2009-05-13 エーザイ・アール・アンド・ディー・マネジメント株式会社 抗ｃｘ３ｃｒ１抗体、抗フラクタルカイン抗体及びフラクタルカインの利用
SE0101082D0 (sv) 2001-03-27 2001-03-27 Astrazeneca Ab Novel use
AU2002323570A1 (en) 2001-08-30 2003-03-10 Chemocentryx, Inc. Bicyclic compounds as inhibitors of chemokine binding to us28
CA2502429A1 (en) 2002-10-31 2004-05-21 Amgen Inc. Antiinflammation agents
TWI306458B (en) 2003-05-30 2009-02-21 Elan Pharma Int Ltd Humanized antibodies that recognize beta amyloid peptide
EP1520586A1 (en) 2003-09-30 2005-04-06 Institut National De La Sante Et De La Recherche Medicale (Inserm) Inhibition of fractalkine or of its receptor for the treatment of atopic allergic diseases
JPWO2005032589A1 (ja) 2003-10-02 2007-11-15 独立行政法人科学技術振興機構 Ｇｖｈｄの予防及び治療
MXPA06003792A (es) 2003-10-07 2006-06-14 Astrazeneca Ab Nuevas 4-amino-tiazolo[4,5-d]-pirimidinas 2-sustituidas, utiles como antagonistas del receptor de quimiocina, especialmente cx3cr1.
EP1810979B1 (en) 2004-09-22 2012-06-20 Kyowa Hakko Kirin Co., Ltd. STABILIZED HUMAN IgG4 ANTIBODIES
EP1806145B1 (en) 2004-10-29 2017-08-16 Eisai R&D Management Co., Ltd. Remedy for inflammatory diseases
UA90707C2 (en) 2005-04-06 2010-05-25 Астразенека Аб Novel 5-substituted 7-amino-[1,3]thiazolo[4,5-d]pyrimidine derivatives
AR053347A1 (es) 2005-04-06 2007-05-02 Astrazeneca Ab Derivados de [1,3]tiazolo[4,5-d]pirimidin-2(3h)-ona 5,7-sustituidos
PT2094728E (pt) 2006-10-26 2013-05-27 Janssen Biotech Inc Métodos de adaptação de anticorpos monoclonais ao ser humano
MX2010002683A (es) * 2007-09-14 2010-03-26 Amgen Inc Poblaciones de anticuerpos homogeneos.

Also Published As

Publication number Publication date
KR101627605B1 (ko) 2016-06-07
MY158481A (en) 2016-10-14
EP2493930A4 (en) 2013-12-04
ZA201203002B (en) 2013-06-26
JP2015027304A (ja) 2015-02-12
CL2015000114A1 (es) 2015-04-10
IL219470A (en) 2017-10-31
AU2010312408A1 (en) 2012-06-21
JP5631991B2 (ja) 2014-11-26
CN102597003B (zh) 2016-03-23
BR112012010266A2 (pt) 2016-12-06
AR109533A2 (es) 2018-12-19
IL219470A0 (en) 2012-06-28
DK2493930T3 (en) 2018-12-17
MX2012005052A (es) 2012-05-29
PL2493930T3 (pl) 2019-03-29
KR20120104560A (ko) 2012-09-21
HRP20181973T1 (hr) 2019-01-25
TW201127401A (en) 2011-08-16
EP2493930B1 (en) 2018-09-19
US20120213799A1 (en) 2012-08-23
PT2493930T (pt) 2018-11-29
LT2493930T (lt) 2019-01-10
JP2013509158A (ja) 2013-03-14
CA2778895A1 (en) 2011-05-05
TWI414308B (zh) 2013-11-11
RU2012122203A (ru) 2013-12-10
CN102597003A (zh) 2012-07-18
RU2569109C2 (ru) 2015-11-20
SMT201800637T1 (it) 2019-01-11
PE20121645A1 (es) 2012-12-06
US8932592B2 (en) 2015-01-13
WO2011052799A1 (en) 2011-05-05
CA2778895C (en) 2018-08-07
NZ599779A (en) 2014-03-28
CY1121167T1 (el) 2020-05-29
CL2012001143A1 (es) 2012-10-05
KR20160066055A (ko) 2016-06-09
KR102099596B1 (ko) 2020-04-10
EP2493930A1 (en) 2012-09-05
AU2010312408B2 (en) 2015-07-09
AR078796A1 (es) 2011-12-07
SI2493930T1 (sl) 2018-12-31
ES2698389T3 (es) 2019-02-04
RS58142B1 (sr) 2019-02-28
UA105073C2 (uk) 2014-04-10
HUE041952T2 (hu) 2019-06-28
PH12012500828A1 (en) 2013-01-07

Similar Documents

Publication Publication Date Title
CY1123145T1 (el) Anti-cd40 αντισωματα
JO3437B1 (ar) أجسام مضادة محسنة مضادة للفراكتالكين البشري واستخداماتها
CY1122278T1 (el) Αντι il-36r αντισωματα
JO3118B1 (ar) تراكيب وطرق لبروتين c5 المتمم يستهدف الأجسام المضادة
EA201791693A1 (ru) Гетеродимерные иммуноглобулины
MY178142A (en) Anti-phf-tau antibodies and their uses
SG184310A1 (en) Antibodies that bind human cd27 and uses thereof
TW201129381A (en) Antibodies against human CSF-1R and uses thereof
MX336682B (es) Anticuerpos contra csf-1r humanos y usos de los mismos.
EA201390929A1 (ru) Антитела к pcsk9 и способы их применения
MX2011011925A (es) Anticuerpos triespecificos o tetraespecificos.
IL228988A (en) Antibody preparations for the treatment of vaccine-related diseases
PH12017500864A1 (en) Anti-notch1 antibodies
MX347454B (es) Anticuerpos monoclonales inhibidores anti-factor xii-xiia.
SG178886A1 (en) Humanized anti-cdcp1 antibodies
PH12013500933A1 (en) Methods and compositions for neural disease immunotherapy
MX2011010012A (es) NUEVOS ANTICUERPOS ANTI-A5ß1 Y SUS USOS.
MY161868A (en) Anti-bv8 antibodies and uses thereof
PH12013500616A1 (en) Antibody compositions and methods of use
MX2015004892A (es) Metodos y composiciones que se relacionan con anticuerpos de receptor anti-il-21.
TN2011000041A1 (en) Compositions and methods for antibodies targeting complement protein c5